TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, SIRT1 inhibition induces p53-mediated CML-LSC apoptosis, while the SIRT inhibitor/TKI combination reduces TKI resistance and suppresses CML progression [97].